Get started
Author

Nikhil Nayee

Observed names: N. Nayee, Nikhil Naik Nayee
ORCID: 0009-0003-1416-089X
Observed ORCID: 0009-0003-1416-089X
OpenAlex ID: A5116904923
Real-World, Evidence-Based, Retrospective Study of Patients Infused with Commercially Released Lifileucel for Advanced Melanoma
2026 · Lilit Karapetyan, Justin Moser, et al. · Transplantation and Cellular Therapy · 2
Corrigendum to “Real-World, Evidence-Based, Retrospective Study of Patients Infused with Commercially Released Lifileucel for Advanced Melanoma” Transplantation and Cellular Therapy (2026)
2026 · Lilit Karapetyan, Justin Moser, et al. · Transplantation and Cellular Therapy
Abstract 7695: Blood-based proteomics analysis for uveal melanoma prognosis
2026 · Abarajithan Chandrasekaran, Nikhil Nayee, et al. · Cancer Research
Real-World, Evidence-Based, Retrospective Study of Patients Infused with Commercially Released Lifileucel for Unresectable or Metastatic Melanoma
2026 · Lilit Karapetyan, Justin Moser, et al. · Transplantation and Cellular Therapy
Real-World, Evidence-Based, Retrospective Study of Patients Infused with Commercially Released Lifileucel for Unresectable or Metastatic Melanoma
2026 · L. Karapetyan, J. Moser, et al. · EJC Skin Cancer
Use of lenvatinib as bridging therapy for patients undergoing treatment with lifileucel: a single institution experience
2025 · M. Challapalli, N. Nayee, et al. · EJC Skin Cancer
PDF
Two-day scheduled break between lymphodepleting chemotherapy and tumor infiltrating lymphocyte therapy infusion: a single institution experience
2025 · J.T. Harris, N. Nayee, et al. · EJC Skin Cancer
Vedolizumab Dose Escalation Resolves Immune Checkpoint Inhibitor–Induced Colitis in Two Patients
2025 · Cong Wang, Nikhil Nayee, et al. · Case Reports in Oncological Medicine
PDF
Works count: 8
Citation count: 2
H-index: 1
I10-index:
Year
Topic
Type